Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer

Journal of Otolaryngology - Head and Neck Surgery

Volumn 39, Issue 2, 2010, Pages 142-149

  Yoon, Tae Mi ^a   Lee, Joon Kyoo ^a   Cho, Jae Shik ^a   Lim, Sang Chul ^a   Chung, Woong Ki ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Chemoradiation; Concurrent chemotherapy; Larynx preservation; Neoadjuvant chemotherapy; Supraglottic carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LARYNX CANCER; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 77949947799     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2009.090054     Document Type: Article

References (23)

1. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ perservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
3. Cox JD, Stetz JA, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
4. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
5. Kaplan EL, Meier PI. A nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
6. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous cell carcinoma. Cancer 1987;60:301-11.
7. Shah JP, Ladd W. Treatment of cancer of the head and neck. CA Cancer J Clin 1995;45:352-68.
8. Lavertu P, Adelstein DJ, Saxton JP, et al. Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience. Arch Otolaryngol Head Neck Surg 1999;125:142-8.
9. Adelstein JD, Tan EH, Lavertu P. Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 1996;24:97-116.
10. Chen AY, Schrag N, Hao Y, et al. Changes in treatment of advanced laryngeal cancer 1985-2001. Otolaryngol Head Neck Surg 2006;135:831-7.
11. Lefebvre JL. Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol 2006;7:747-55.
12. American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693-704.
13. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new threatment paradigm. J Clin Oncol 2006;24:593-8.
14. Majem M, Mesia R, Manos M, et al. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma. Laryngoscope 2006;116:1651-6.
15. Bourhis J, LeMaitre A, Pignon J, for MACH-NC MARCH Groups. Impact of age on treatment effect in locally advanced head and neck cancer: two individual patient data meta-analyses. Proc Am Soc Clin Oncol 2006;24:280s.
16. Clayman GL, Eicher SA, Sicard MW, et al. Surgical outcomes in head and neck cancer patients 80 years of age and older. Head Neck 1998;20:216-23.
17. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994;29:519-23.
18. Begg AC, van der Kolk PJ, Dewit L, et al. Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1986;50:871-84.
19. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Lancet 2000;355:949-55.
20. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase II randomized trial comparing concurrent chemotherapy and radiotherapy with radiatherapy alone in resectable stage III and IV sqaumous cell head and neck cancer: preliminary results. Head Neck 1997;19:567-75.
21. Taguchi T, Tsukuda M, Mikami Y, et al. Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol (Stockh) 2006;126:408-13.
22. Posner MR, Hershock DM, Blajman CR, et al, TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
23. Ahn JS, Cho SH, Kim OK, et al. The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. Cancer Res Treat 2007;39:93-8.